

NIH GUIDE

for GRANTS and CONTRACTS

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Vol. 9, No. 13, October 31, 1980

IN THIS ISSUE:

- Information Items
Index - OERT, FOIA Page 1
- Biomedical Research Support Grant Applications
for Fiscal Year 1981
Division of Research Resources
Application receipt date: January 1, 1981
Index - DRR Page 2
- NIGMS Shared Instrumentation Grants
National Institute of General Medical Sciences
Application receipt date: February 15
Index - NIGMS Page 4
- Basic and Clinical Research Studies on Ocular
Melanoma Grant Applications
National Eye Institute and
National Cancer Institute
Index - NEI & NCI Page 8
- Research Training and Development Areas and
Types of Awards Available
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
Index - NHLBI Page 12

HAVE YOU MOVED?

If your present address differs from that shown on the address label, please send your new address to: Grants and Contract Guide Distribution Center, National Institutes of Health, Room B3BN10, Building 31, Bethesda, Maryland 20205, and attach your address label to your letter. Prompt notice of your change of address will prevent your name from being removed from our mailing list.

The GUIDE is published at irregular intervals to announce scientific initiatives and to provide policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in grants and contracts activities administered by the National Institutes of Health.

Two types of supplements are published by the respective awarding units. Those printed on yellow paper concern contracts: solicitations of sources and announcement of availability of requests for proposals. Those printed on blue paper concern invitations for grant applications in well-defined scientific areas to accomplish specific program purposes.

INFORMATION ITEMS

NIH EXTRAMURAL PROGRAMS Publication Available

The NIH Office of Extramural Research and Training announces the availability of the **NIH Extramural Programs** brochure. This publication, which replaces the earlier Guide to NIH Programs and Awards, is a compendium of the scientific programs of the NIH components that award grants and contracts. It indicates current areas of research emphasis, highlights the special interests of each awarding component, and identifies specific NIH office: one may contact for further information.

This publication is being mailed to all current recipients of the **NIH Guide for Grants and Contracts** (including supplements to the **Guide**), all principal investigators of current NIH grants and contracts, and members of chartered NIH advisory committees. Persons who wish to receive the **NIH Extramural Programs**, but are not included in any of the above categories, may obtain a copy by writing to:

Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Bethesda, Maryland 20205
Telephone: (301) 496-7441

Court Denies Request for Names of Unsuccessful Grant Applicants

On August 22, 1980 the District Court of Massachusetts ruled that the National Cancer Institute (NCI) was not required to disclose the names of unsuccessful applicants for grants. This court decision confirms the longstanding policy that NIH has followed in refusing to give out information about unsuccessful applicants and about applications that have never been funded.

In 1976, Dr. George M. Kurzon asked NCI for the names of scientists whose grant applications had been turned down. Dr. Kurzon's request was denied by the Department on the basis of Exemption 6 of the Freedom of Information Act (FOIA) which protects "personnel and medical files and similar invasion of personal privacy." Dr. Kurzon then filed suit in Massachusetts to force the Department to release the names. The above-mentioned decision was the outcome of that suit.

The Court noted that Exemption 6 requires the Government to balance the public interest that would be served by disclosure against the potential invasion of individual privacy. Kurzon contended that disclosure of the unsuccessful applicants (and their protocols) would help him show that the peer review system was unfairly biased against innovative and creative ideas. The Court rejected that argument and agreed with DHEW that the names were "sensitive" and negative inferences could be drawn which would affect the applicants' careers and ability to pursue new opportunities.

ANNOUNCEMENT

BIOMEDICAL RESEARCH SUPPORT GRANT APPLICATIONS FOR FISCAL YEAR 1981

DIVISION OF RESEARCH RESOURCES

Application receipt date: January 1, 1981

BACKGROUND INFORMATION

The Biomedical Research Support Grant (BRSG) Program is specifically designed to complement other forms of biomedical research support. It enables institutions to respond quickly and effectively to new opportunities and unpredictable requirements, to enhance creativity, to encourage innovation, to provide for pilot studies and initial support of new investigators, and to improve research resources - both physical and human. Awards are used to support short-term, nonrecurring, low-cost or core resource support needs that are not feasibly or appropriately supported by other PHS grant programs. Allocation of the funds to any biomedical research activity is decided by the grantee institution.

ELIGIBILITY

Awards are made to non-profit institutions (not directly to individual investigators). Health professional schools; academic institutions other than health professional schools; hospitals; state and municipal health agencies; and research organizations may apply if the institution received a minimum of three allowable PHS biomedical or health-related behavioral research grants, totaling \$200,000 (including direct and indirect costs), awarded during FY 1980 (October 1, 1979 through September 30, 1980). Federal institutions and institutions located in a foreign country are not eligible.

AWARD CONDITIONS

The BRSG award is for one year and must be renewed annually. The start date is April 1. It is estimated that approximately 500 BRSG awards will be made in FY 1981.

The BRSG program is described in the Catalog of Federal Domestic Assistance, Number 13.337, Biomedical Research Support. Grants will be awarded under the authority of the Public Health Service Act, Section 301 (42 USC 241) and administered under PHS grant policies and Federal Regulations 45 CFR Part 74 and the Biomedical Research Support Grant Information Statement and Administrative Guidelines. This program is not subject to A-95 Clearinghouse or Health Systems Agency Review.

The amount of each BRSB award is based upon a formula that is applied to the total of direct and indirect costs awarded for allowable PHS research grants.

METHOD OF APPLYING

BRSB application kits (Form NIH-147-1) will be mailed on or about November 28 to all current BRSB grantees and to those institutions that appear to be eligible according to NIH/PHS records.

If an institution believes that it is eligible to apply for a BRSB and does not receive an application by December 10, please write or call:

Biomedical Research Support Program
Division of Research Resources
Office of Grants and Contracts Management
National Institutes of Health
Bethesda, Maryland 20205

Attention: Mrs. Gilda Polletto
Grants Management Specialist

Telephone: (301) 496-5131

Completed BRSB applications must be received by January 1, 1981.

ANNOUNCEMENT

NIGMS SHARED INSTRUMENTATION GRANTS

NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

Application receipt date: February 15

The National Institute of General Medical Sciences announces the availability of a grant mechanism for the acquisition of new, or the updating of existing, major research instruments which cannot be justified fully for use on a single project but which can serve several projects on a shared basis. The intent of this grant is to provide NIGMS grantees with better access to modern instrumentation and to encourage the sharing of expensive equipment. Although the needs of NIGMS grantees are the primary basis on which shared instrumentation grants will be awarded, access to the instruments provided by this mechanism will not be restricted to NIGMS grantees nor to investigators within the particular grantee institution. Within any given year, limited funds may be available for this type of grant. Competing demands of regular research grants on the Institute's budget will be a factor in determining the number of awards to be made.

MECHANISM OF SUPPORT

The NIGMS Shared Instrumentation Grants can support any kind of instrumentation or equipment provided that each item or system requested has a cost of at least \$30,000. Grants will be awarded for a period of up to three years and are not renewable. Besides the cost of the instrumentation, support for maintenance of the equipment may be requested for the period of the grant. In cases where at least 20% of the planned use of the equipment will be by users other than the major user group (see eligibility, below), support for technical assistance up to a maximum of one half the salary of a qualified technician may be requested for up to 3 years. Provisions for continued maintenance of the equipment and for technical support beyond the period of the grant must be made by the applicant institution and these plans must be detailed in the application.

Although there is no upper limit to the cost of instrumentation that can be requested, the maximum contribution from NIGMS in the equipment category will be \$200,000 for any one award. If this amount does not cover the total cost of the

This program is described in the Catalog of Federal Domestic Assistance Numbers 13.821, Physiology and Biomedical Engineering; 13.859, Pharmacology-Toxicology Research; 13.862, Genetics Research; and 13.863, Cellular and Molecular Basis of Disease Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency Review.

equipment, an award will not be made unless the remainder of the funding is assured. Assurance of co-funding, signed by an appropriate institution official, must be presented prior to the issuance of an award.

Since the evaluation of an application involves several users and depends so heavily on the particular conditions at a given institution, a grant for shared instrumentation will not be transferrable.

ELIGIBILITY

The principal investigator on an application for a shared instrumentation grant must hold an active NIGMS research grant and must assume responsibility for the instrument and for all related administrative functions. Since the grant is primarily designed to serve NIGMS grantees, the applicant must show a clear need for the instrumentation by projects supported by NIGMS research grants and demonstrate that these projects will use the instrumentation for a substantial portion of the available instrument time. A major user group of three or more investigators (including the Principal Investigator) must be identified who will use the equipment at least 75% of the time. At least one of this group must have sufficient expertise to instruct others in use of the equipment and to oversee its appropriate use. Each major user must have NIH research support at the time of award and at least one half, but a minimum of two, of the major users must hold NIGMS grants. If the major user group does not need the equipment for 100% of the available instrument time, up to 25% of time may be made available to other users. Not all of these other users need have NIH grant support.

APPLICATION PROCEDURES

Form PHS 398 should be used for applying. Application kits are available from most institutional business offices or from the Division of Research Grants, NIH. In item 1 of the face page, write: "NIGMS SHARED INSTRUMENTATION GRANT." The application should identify the major user group as well as other potential users.

All projects (both those of the major user group and those of other users) for which the instrumentation will be used must be described and their support identified by agency, grant number and dollar support per year. An estimate of the percentage use for each project should be provided. In cases where the instrumentation will be available to users other than the major user group, a plan for providing access to these users should be detailed.

The justification should include a description of similar instrumentation presently available on or near the campus and an explanation of why additional equipment or updated equipment is required. A specific plan for continued upkeep of the equipment beyond the award period and for institutional commitment towards this must be presented and will be an important element in the evaluation of the application. Annual reports describing the use of the instrument, listing all users and demonstrating the contribution of the instrumentation to the research of the major user group will be required for the period of the grant.

CRITERIA FOR REVIEW

The following factors will be considered in the peer review of shared instrumentation grants.

1. Need for instrumentation. The needs of both the major user group and other potential users will be considered in assessing need.
2. Scientific merit of the research for which the instrumentation is required.
3. Appropriate expertise within the major user group for use of the instrumentation.
4. Adequacy of arrangements for sharing of the equipment and for making it accessible to users other than the major user group when this is part of the justification for the instrument.
5. Institutional commitment for continued support and maintenance of the equipment - this may be through user charges if adequate grant support can be demonstrated.

CRITERIA FOR AWARDS

Due to the limitation of funds available to this program, additional criteria will be considered by the Institute in making funding decisions. They may include:

1. Geographic distribution of awards.
2. Balance between types of instruments supported.

RECEIPT AND REVIEW

There will be one receipt date annually - February 15 of each year. Review will be by review groups specially constituted according to the types of applications received. Applications will go to Council in October of the same year and awards will be made no earlier than December 1 of the same year.

A letter of intent must be submitted by December 15, 1980 (in subsequent years by November 15) to:

Dr. Marvin Cassman
National Institute of General Medical Sciences
National Institutes of Health
Bethesda, Maryland 20205
Telephone: (301) 496-7463

This letter should contain information about the instrument to be applied for, its cost, the major user group and a brief justification of need. Such information will help in planning for the review of applications and alert Institute staff to special circumstances that may need to be addressed prior to submission of the application.

At the time a formal application is mailed to the Division of Research Grants, the applicant should inform the individual designated above, in writing, that the application has been submitted. The original and six copies of the application should be sent or delivered to:

Application Receipt Office
Division of Research Grants
National Institutes of Health
Room 240, Westwood Building
5333 Westbard Avenue
Bethesda, Maryland 20205

ANNOUNCEMENT

BASIC AND CLINICAL RESEARCH STUDIES ON OCULAR MELANOMA

GRANT APPLICATIONS

NATIONAL EYE INSTITUTE AND NATIONAL CANCER INSTITUTE

The Retinal and Choroidal Diseases Branch of the National Eye Institute in conjunction with the Cancer Biology Branch and the Cancer Therapeutic Evaluation Program of the National Cancer Institute encourage the submission of grant applications for research on ocular tumors. Specifically, the Institutes would like to receive applications for research which have potential for expanding knowledge of the biology, natural history, epidemiology, diagnosis, and treatment of ocular melanoma, as well as the natural history, management and biology of this disorder.

It is expected that such information will add to our understanding of how to manage ocular melanoma patients appropriately. Research on the characteristics of tumor cells is expected to provide information on ocular melanomas as well as on other pigmented cells with abnormal growth properties.

I. PURPOSE AND SCOPE

Ocular melanoma is the most common primary intraocular malignancy in adults and comprises over eighty percent of all eye malignancies. In the United States, the annual incidence of ocular melanoma is six cases per million people. Those tumors not only cause blindness, but can also cause death if metastasis occurs. Because of the importance of ocular melanoma, the National Eye Institute, upon recommendations of the National Advisory Eye Council, convened a Task Force in April 1980 to review critically the recent scientific literature on this subject and to recommend what research is most needed to solve some of the critical problems associated with this disease. (Proceedings from this meeting were published in the November 1980 issue of the American Journal of Ophthalmology.)

This program is described in the Catalog of Federal Domestic Assistance, 13.396, Cancer Biology Research; and 13.867, Choroidal Diseases Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency Review.

Listed below are some examples of research areas which are expected to lead to better understanding of the biology of uveal melanomas and to determining how to manage this ocular disorder appropriately.

- * Epidemiological studies to determine the risk factors associated with uveal melanoma.
- * Natural history studies to determine the nature and progression of this disease.
- * Development of techniques and biological assays to monitor tumor growth serially in vivo.
- * Investigations to determine whether the histopathological features of the tumor can be correlated with the natural history of the disease or with prognosis.
- * Development of methods to improve the cellular criteria for categorizing tumors by the Callender classification and to expand the Callender classification to an ultrastructural level.
- * Randomized controlled clinical trial to determine the effect of enucleation on the natural history of primary ocular melanoma. Patients eligible for the study should be limited to those with a poor prognosis, such as patients with large melanomas or those having melanomas with extrascleral extensions.
- * Studies to define the immunologic status of the individual in relation to efficacy of treatment of disease progression or regression.
- * Investigations of the biological, biochemical, and immunologic properties of uveal melanomas utilizing established cell lines and appropriate animal models.

Applications for grants are invited from investigators in all relevant disciplines, as well as from investigators new to this problem area. Applications which propose collaborations between basic and clinical research scientists are particularly encouraged.

II. METHOD AND CRITERIA OF REVIEW

Applications will be received by the NIH Division of Research Grants, referred to an appropriate Initial Review Group for scientific merit review, and assigned to the appropriate Institute. Referral decisions will be governed by the normal programmatic considerations as specified in the Referral Guidelines of the NIH Division of Research Grants.

Applications submitted in response to this announcement will be reviewed and funded on a nationwide basis in competition with all other research grant applications, and in accord with the usual National Institutes of Health peer review procedures. Applications proposing clinical trials will

be evaluated according to the criteria developed by the National Eye Institute.* Such applications should include a clear statement of the hypothesis to be tested, a detailed rationale for the proposed study, an indication of the number of patients needed for statistically valid results, the anticipated recruitment population and location, and an efficient network for sharing resources. A detailed manual of procedures is required for all proposed clinical trials and must be submitted as part of the application.

Applications will be accepted in accordance with the usual NIH receipt dates for new applications as follows:

APPLICATION RECEIPT	INITIAL REVIEW	COUNCIL REVIEW	EARLIEST START DATE
March 1	June	Sept./Oct.	Dec. 1
July 1	Oct./Nov.	Jan. /Feb.*	April 1*
Nov. 1	Feb./March*	May*	July 1

*Of the year following application receipt.

III. METHOD OF APPLYING

Applications should be submitted on form PHS 398, which is available in the business or grants and contracts office at most academic and research institutions, or from the Division of Research Grants, NIH. In responding to this program announcement, the phrase "**NEI and NCI Ocular Melanoma**" should be typed in the space provided on page one of the application.

The original and six copies of the application should be sent or delivered to:

Application Receipt
Division of Research Grants
National Institutes of Health
Room 240, Westwood Building
Bethesda, Maryland 20205

The National Eye Institute and the National Cancer Institute encourage potential applicants to communicate with their staff. Inquiries concerning this announcement should be directed to one of the following:

Bettie J. Graham, Ph.D.
Retinal-Vascular Disorders Program
National Eye Institute
Room 6A52, Building 31
Bethesda, Maryland 20205
Telephone: (301) 496-5983

*Copies of the National Eye Institute's "Criteria for Review of Grant Applications Involving Clinical Trials" may be obtained by contacting the NEI staff person listed at the end of this announcement.

John S. Macdonald, M.D.
Cancer Therapy Evaluation Program
National Cancer Institute
Room 4C37, Landow Building
Bethesda, Maryland 20205
Telephone: (301) 496-6138

Brian Kimes, Ph.D.
Chief, Basic Cancer Biology Section

or

Colette Freeman, Ph.D.
National Cancer Institute
5333 Westbard Avenue
Bethesda, Maryland 20205
Telephone: (301) 496-7028

ANNOUNCEMENT

RESEARCH TRAINING AND DEVELOPMENT AREAS AND TYPES OF AWARDS AVAILABLE

THE DIVISION OF HEART AND VASCULAR DISEASES

THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

This announcement consolidates and summarizes the current research training and development programs of the Division of Heart and Vascular Diseases. It is a summary intended to be helpful to potential applicants. It is not an announcement of any new programs or initiatives. (The number of awards made annually will depend on merit and programmatic emphasis of proposals received, as well as the availability of funds.)

Research training may be in fundamental studies of basic processes and functions, behavioral studies, including risk factor modification (e.g. diet, smoking), genetics (including studies of populations), and primary and secondary prevention or clinical investigations directed toward increasing knowledge and understanding in any cardiovascular area. All Division activities are categorized into one or more of the following program areas:

- Hypertension
- Arteriosclerosis
- Coronary Heart Disease
- Cardiovascular Aspects of Diabetes
- Arrhythmias
- Heart Failure and Shock
- Cerebrovascular Disease
- Peripheral Vascular Disease
- Congenital and Rheumatic Heart Disease
- Cardiomyopathies and Infections of the Heart
- Circulatory Assistance
- Cardiovascular Devices and Technology

The awards summarized below may be used for the support of research training and development in various areas listed above.

These programs are described in the Catalog of Federal Domestic Assistance number 13.837, Heart and Vascular Diseases Research. Awards will be made under the authority of the Public Health Service Act, Section 472 (42 USC 289-1), administered under PHS grants policy and Federal Regulations 42 CFR Part 66, and Section 301 (Public Law 78-410, as amended; 42 USC 241), administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. These programs are not subject to A-95 Clearinghouse or Health Systems Agency Review.

I. National Research Service Award Programs

A. Institutional Research Training Grant Award

- * Predoctoral and postdoctoral trainees.
- * Selection of training institution by national competition.
- * Institutional selection of trainees.
- * Trainee support includes stipend (\$5,040 per year for predoctoral trainees; \$13,380-\$18,780 per year for postdoctoral trainees depending on relevant postdoctoral experience), tuition, fees, hospitalization and travel.
- * Stipend supplementation is allowed from non-federal funds.
- * Institutional allowance (\$3,000 per year for predoctoral trainees; \$5,000 per year for postdoctoral trainees); indirect cost is limited to 8 percent.
- * Duration of award may be up to five years.
- * Maximum predoctoral training duration is five years.
- * Maximum postdoctoral training duration is three years.
- * Each month of NRSA-financed training requires a month of payback activity in biomedical or behavioral teaching and/or research.
- * Receipt dates for applications are:

Advisory Council Review:

-February 1
-June 1
-October 1

-October
-February
-May

B. Individual Postdoctoral Fellowship Award

- * Postdoctoral trainees only.
- * Selection by national competition.
- * Stipend is \$13,380-\$18,780 depending on relevant postdoctoral experience.
- * Stipend supplementation is allowed from non-federal funds.
- * Institutional allowance of \$5,000 per year; \$2,000 to Federal laboratories.
- * Duration of award is one to three years.
- * Maximum training duration is 36 months.
- * Each month of NRSA-financed training requires a month of payback activity in biomedical or behavioral teaching and/or research.
- * Receipt dates for applications are:

Results announced in:

-February 1
-June 1
-October 1

-October
-February
-May

C. Senior Research Fellowship Award

- * To make major changes in direction of research careers or to acquire new research capabilities.

- * Experienced scientists only (at least seven years of relevant postdoctoral research or professional experience).
- * Selection by national competition.
- * Stipend will be negotiated up to \$30,000 per year.
- * Stipend supplementation is allowed from non-federal funds.
- * Institutional allowance of \$5,000 per year.
- * Duration of award is normally twelve months.
- * Each month of NRSA-financed training requires a month of payback activity in biomedical or behavioral teaching and/or research.
- * Receipt dates for applications are: Results announced in:

-February 1	-October
-June 1	-February
-October 1	-May

D. Minority Hypertension Research Development Summer Award

- * Minority school faculty member and/or graduate student research development in hypertension.
- * Recruitment, nomination, and selection of trainees by hypertension training center and minority school.
- * Selection of institutions by national competition.
- * Trainee support includes NRSA stipend, tuition, fees, hospitalization and travel.
- * Stipend supplementation is allowed from non-federal funds.
- * Institutional allowance; indirect cost is up to 8 percent.
- * Duration of award is up to five years.
- * No payback provision for training periods of up to three months.

E. Short-Term Research Training in Health Profession Schools

- * To increase the number of clinical investigators in biomedical and behavioral research careers.
- * Qualified health professional students only.
- * Selection of training institutions by national competition.
- * Institutional selection of trainees.
- * Stipend support for trainees (\$420 per month); institutional allowance up to \$250.00 per trainee per month.
- * Stipend supplementation is allowed from non-federal funds.
- * No award made for fewer than four nor more than thirty-two students per year.
- * Duration of award is up to five years.
- * No payback provision for training periods of up to three months.
- * Receipt date of May 1 each year. February Advisory Council review.

II. The Research Career Development Programs

A. Research Career Development Award

- * Research career development of biomedical or behavioral scientists with outstanding research potential.

- * Cannot be an established investigator when awarded.
- * Must have at least three years postdoctoral experience.
- * Selection by national competition.
- * Salary support of up to \$30,000 per year plus fringe benefits.
- * Supplementation is allowed from non-federal funds.
- * Duration of award is five years; non-renewable.
- * Must devote essentially full time to research and research-related activities.
- * Receipt dates for applications are: Advisory Council Review:

-February 1
-June 1
-October 1

-October
-February
-May

B. Preventive Cardiology Academic Award

- * To encourage development of high quality preventive cardiology curriculum in schools of medicine and osteopathy that will attract outstanding students to preventive cardiology research and medical practice.
- * The awardee must hold an academic appointment at a school of medicine or osteopathy and have clinical training and/or research experience in cardiology.
- * The institution must sponsor a candidate with competence in clinical cardiology and provide the awardee with time to acquire the educational skills for personal development as a teacher and for the development of the preventive cardiology curriculum.
- * Awards are limited to one for each eligible school with a project period of five years.
- * Awardee must devote at least 50 percent time or effort.
- * Salary support of up to \$30,000 per year plus fringe benefits.
- * Supplementation is allowed from non-federal funds.
- * Award provides funds for some other operating costs.
- * Annual receipt date of April 1 for starting date of July 1 the following year.

C. Clinical Investigator Award

- * To encourage newly trained clinicians to develop clinical and basic research interests and skills in the area of cardiovascular diseases.
- * Clinically-trained physicians are candidates for the award.
- * Selection by national competition.
- * The grantee institution must have strong, well-established research and training programs.
- * Candidates must have one or more sponsors or advisors from the grantee institution.
- * Salary is up to \$25,000 for first year, with maximum salary of \$30,000 for future years plus fringe benefits.
- * Supplementation is allowed from non-federal funds.
- * Support for five years; full time effort; non-renewable.

- * Awardee and sponsor required to submit detailed progress report at end of third year.
- * Annual receipt date is August 1 for starting date of July 1 the following year.

D. Special Emphasis Research Career Award: Diabetes Mellitus

- * To encourage qualified individuals to develop interdisciplinary research skills in Diabetes Mellitus.
- * Applicant must hold an M.D. or equivalent professional degree with a minimum of three years post-M.D. experience or two years post-M.D./Ph.D. experience.
- * Selection by national competition.
- * Support for five years; non-renewable.
- * Full-time salary support up to a maximum of \$30,000 per year.
- * Supplementation is allowed from non-federal funds.
- * Research support for first three years up to a maximum of \$8,000 per year; research support for 4th and 5th year up to a maximum of \$20,000 per year.
- * Annual receipt date of June 1. Advisory Council review in February.

E. New Investigator Research Award

- * To encourage new investigators in basic or clinical science disciplines to develop their research interest and capabilities in biomedical and behavioral research.
- * Doctoral degree by time of award.
- * Restricted to applicants who have not previously been principal investigators on a PHS supported project.
- * Concurrent applications not permitted for research grant award, research training or research development award.
- * Duration of award up to three years; non-renewable.
- * Salary support up to \$25,000 per year; total direct cost must not exceed \$107,500 for three year period - no more than \$37,500 in any one year.
- * Supplementation is allowed from non-federal funds.
- * Selection by national competition.
- * Receipt dates for applications are: Advisory Council Review:

-March 1
-July 1
-November 1

-October
-February
-May

Further information regarding the above programs can be obtained from:

Research Training and Development Branch
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland 20205
Telephone: (301) 496-1724